Trial Profile
Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Camsirubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Gem Pharmaceuticals
- 14 Nov 2017 Results published in the Monopar Therapeuticsthe Media Release.
- 12 Feb 2015 Results published in the Investigational New Drugs.
- 04 Aug 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov.